GenSci showcases the innovative pipelines at ChinaBio?
Time
2024-09-23
Readership
3395
Share
September 10, Shanghai—Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) showcased its series of innovative pipelines at the leading event for cross-border partnerships, ChinaBio?. John L. Xu, Executive Vice President, Discovery Research in Immunology and Oncology of GenSci, presented the latest pipeline outcomes at this conference. Several innovative modalities for main diseases have attracted great attention.
John L. Xu is presenting the latest pipeline outcomes at this conference
The innovative pipelines of GenSci shown at this conference cover key disease areas such as oncology, immunology, and endocrinology, which includes potential First-in-Class (FIC) and Best-in-Class (BIC) innovative drugs. The company's oncology portfolio features ADCs and small molecule drugs for solid tumors like prostate cancer, breast cancer and ovarian cancer. GenSci also presented two siRNA programs and a PD-1 agonist program. GenSci098, which recently obtained the implied license for clinical trials from the FDA, was also highlighted. These above-mentioned drugs are likely to be FIC or BIC.
Mr. Xu extended that GenSci is eager to collaborate with more multinational corporations and leading pharmaceutical companies on R&D, commercialization, and globalization strategies to expand into broader international markets.
As China's leading life sciences partnering conference, ChinaBio? aims to accelerate cross-border collaborations within China and provides the global biopharma community with opportunities to expand their reach into the Chinese life science market through such partnerships. The forum brings together decision-makers, executives, investors, and industry experts from the life sciences sector, who share their insights and experiences on leading companies and innovative startups both in China and globally. The introduction of GenSci's innovative pipeline at this event signifies a significant step for the company, as it connects with international MNCs and transitions from a domestic leader to a global player.
